CAS#:2023788-19-2
TR
Size
Research Profile
TR
Literature-based research context for laboratory reference only.
TR is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly. Its twin-incretin pharmacology has generated significant research interest in metabolic disease, covering insulin secretion, glucagon suppression, gastric emptying, and adipose tissue biology.
Selected literature
- Coskun et al., 2018, Molecular Metabolism.
This page is provided for laboratory reference and literature review only. The material is not presented as a consumer product, medical treatment, diagnostic tool, or recommendation for human or animal use.
Overview
TR is presented here as a laboratory reference entry. The Research Profile summarizes literature-based biological context, while this Overview documents the identity record, specification set, preparation format, and quality-reference information available on the page.
The identity block lists CAS number 2023788-19-2, molecular formula C₂₂₅H₃₄₈N₄₈O₆₈, and molecular weight 4,813.5 Da. The material record is paired with ≥99% purity information and a lyophilized presentation for reference review.
Available specification labels include 2mg, 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg, 100mg, and 120mg. The active selection is 2mg; changing the selector updates the visible specification label and COA lot references while preserving the same research-reference context.
For the active selection, the page currently shows 1 active COA lot reference. COA links, when present, are retained for batch-level purity, identity, and quantity review, while packaging and storage details remain separated in Structure & Identity.